Skip to main content

Advertisement

SpringerLink
Log in

Lipid-lowering therapies in the management of acute coronary syndromes

  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Despite the significant advances made in the treatment of acute coronary syndromes (ACS) with antiplatelet and antithrombotic therapy, the risk of serious complications remains high, especially in the first few months following an acute coronary event. Although lipid-lowering therapy in patients with significant risk factors (primary prevention) or stable coronary disease (secondary prevention) is known to improve long-term survival, patients with a recent ACS were specifically excluded from the early statin trials. However, the use of lipid-lowering agents (principally statins) during hospitalization or in the period immediately following an acute coronary event has recently been studied. Statin therapy in this setting has been shown to reduce angina, rehospitalization, and mortality. Improved outcomes associated with lipid-lowering therapy in ACS may be mediated through beneficial effects on plaque stabilization, endothelial function, inflammation, and thrombus formation. This paper reviews the evidence supporting the potential benefits and mechanisms of statin therapy in the management of ACS. Clinical guidelines to achieve optimal lipid management are also discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. American Heart Association: 2002 Heart and Stroke Statistical Update. Dallas: American Heart Association; 2001.

    Google Scholar 

  2. Colquhoun D: Unstable angina: a definitive role for statins in secondary prevention. Int J Clin Pract. 2000, 54:383–389.

    PubMed  CAS  Google Scholar 

  3. Libby P: Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 2001, 104:365–372.

    PubMed  CAS  Google Scholar 

  4. Yeghiazarians Y, Braunstein JB, Askari A, Stone PH: Unstable angina pectoris. N Engl J Med. 2000, 342:101–114.

    Article  PubMed  CAS  Google Scholar 

  5. Theroux P, Fuster V: Acute coronary syndromes. Unstable angina and non-Q-wave MI. Circulation. 1998, 97:1195–1206.

    PubMed  CAS  Google Scholar 

  6. Weitz JL, Bates SM: Beyond heparin and aspirin: new treatments for unstable angina and non-Q-wave MI. Arch Intern Med. 2000, 160:749–758.

    Article  PubMed  CAS  Google Scholar 

  7. Sacks FM, Pfeffer MA, Moye LA, et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996, 335:1001–1009.

    Article  PubMed  CAS  Google Scholar 

  8. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994, 344:1383–1389.

    Article  Google Scholar 

  9. LIPID Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339:1349–1357.

    Article  Google Scholar 

  10. Shepherd J, Cobbe SM, Ford I, et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995, 333:1301–1307.

    Article  PubMed  CAS  Google Scholar 

  11. Downs JR, Clearfield M, Weis S, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998, 279:1615–1622.

    Article  PubMed  CAS  Google Scholar 

  12. Rubins HB, Robins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999, 341:410–418.

    Article  PubMed  CAS  Google Scholar 

  13. Collins R, Peto R, Armitage J: The MRC/BHF Heart Protection Study: preliminary results. Int J Clin Pract. 2002, 56:53–56.

    PubMed  Google Scholar 

  14. Levine GN, Keaney Jr JF, Viata JA: Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms. N Engl J Med 1995, 332:512–521.

    Article  PubMed  CAS  Google Scholar 

  15. Egashira K, Hirooka Y, Kai H, et al.: Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation. 1994, 89:2519–2524.

    PubMed  CAS  Google Scholar 

  16. Treasure CB, Klein JL, Weintraub WS: Beneficial effects of cholesterol- lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995, 332:481–487.

    Article  PubMed  CAS  Google Scholar 

  17. Anderson TJ, Meredith IT, Yeung AC, et al.: The effect of cholesterol- lowering and anti-oxidant therapy on endotheliumdependent vasomotion. N Engl J Med 1995, 332:488–493.

    Article  PubMed  CAS  Google Scholar 

  18. O’Driscoll G, Green D, Taylor RR: Simvastatin, an HMG-coenzyme A reductase inhibitor improves endothelial function within 1 month. Circulation. 1997, 95:1126–1131.

    PubMed  CAS  Google Scholar 

  19. Dupuis J, Tardif JC, Cernacek P, Theroux P: Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: the RECIFE trial. Circulation. 1999, 99:3227–3233.

    PubMed  CAS  Google Scholar 

  20. Laufs U, Wassmann S, Hilgers S, et al.: Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am J Cardiol. 2001, 88:1306–1307.

    Article  PubMed  CAS  Google Scholar 

  21. Marchesi S, Lupattelli G, Siepi D, et al.: Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women. J Cardiovasc Pharmacol. 2000, 36:617–621.

    Article  PubMed  CAS  Google Scholar 

  22. Tannous M, Chenung R, Vignini A, Mutus B: Atorvastatin increases ecNOS levels in human platelets of hyperlipidemic subjects. Thromb Haemost. 1999, 82:1390–1394.

    PubMed  CAS  Google Scholar 

  23. Davis ME, Harrison DG: Cracking down on caveolin: role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in modulating endothelial cell nitric oxide production. Circulation 2001, 103:2–4.

    PubMed  CAS  Google Scholar 

  24. Bustos C, Hernandez-Presa A, Ortego M, et al.: HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol. 1998, 32:2057–2064.

    Article  PubMed  CAS  Google Scholar 

  25. Bickel C, Rupprecht HJ, Blankenberg S, et al.: Influence of HMG-CoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion. Int J Cardiol 2002, 82:25–31.

    Article  PubMed  Google Scholar 

  26. Inoue I, Goto S, Mizotani K, et al.: Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase- 2, and p22phox by regulation of peroxisome proliferator- activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci. 2000, 67:863–876.

    Article  PubMed  CAS  Google Scholar 

  27. Brull DJ, Sanders J, Rumley A, et al.: Statin therapy and the acute inflammatory response after coronary artery bypass grafting. Am J Cardiol. 2001, 88:431–433.

    Article  PubMed  CAS  Google Scholar 

  28. Ridker PM, Rifai N, Lewenthal SP: Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation. 2001, 102:1191–1193.

    Google Scholar 

  29. Jilial I, Stein D, Balis D, et al.: Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive Creactive protein levels. Circulation. 2001, 103:1933–1935.

    Google Scholar 

  30. Koh KK: Effects of HMG-CoA reductase inhibitor on hemostatis. Int J Cardiol. 2000, 76:23–32.

    Article  PubMed  CAS  Google Scholar 

  31. Lacoste L, Lam JYT, Hung J, et al.: Hyperlipidemia and coronary disease: correction of the increased thrombogenic potential with cholesterol reduction. Circulation. 1995, 92:3172–3177.

    PubMed  CAS  Google Scholar 

  32. Stenestrand U, Wallentin L, for the Swedish Registry of Cardiac Intensive Care (RIKS-HIA): Early statin treatment following acute MI and 1-year survival. JAMA. 2001, 285:430–436. This observational study included over 20,000 patients with acute MI. Results demonstrated that early initiation of statin therapy is associated with reduced 1-year mortality.

    Article  PubMed  CAS  Google Scholar 

  33. Aronow HD, Topol EJ, Roe MT, et al.: Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet. 2001, 357:1063–1068.

    Article  PubMed  CAS  Google Scholar 

  34. Bybee KA, Wright RS, Williams BA, et al.: Effect of concomitant or very early statin administration on in-hospital mortality and reinfarction in patients with acute MI. Am J Cardiol. 2001, 87:771–774.

    Article  PubMed  CAS  Google Scholar 

  35. Cannon CP, McCabe CH, Bentley J, Braunwald E: Early statin therapy is associated with markedly lower mortality in patients with acute coronary syndromes: observations from OPUS-TIMI 16 [abstract]. J Am Coll Cardiol. 2001, 87 (Suppl A):334A.

    Google Scholar 

  36. Arntz H-R, Agrawal R, Wunderlich W, et al.: Beneficial effects of pravastatin (± colestyramine/niacin) initiated immediately after a coronary event (the randomized lipid-coronary artery disease [L-CAD] study). Am J Cardiol. 2000, 86:1293–1298.

    Article  PubMed  CAS  Google Scholar 

  37. Schwartz GG, Olsson AG, Ezekowitz MD, et al.: Effects of atorvastatin0 on early recurrent ischemic events in acute coronary syndromes: the MIRACL study. JAMA. 2001, 285:1711–1718. One of earliest studies assessing the impact of statin treatment initiated soon after an acute coronary event. Results demonstrated that early treatment with atorvastatin 80 mg/d reduced recurrent ischemic events in the first 16 weeks.

    Article  PubMed  CAS  Google Scholar 

  38. Sacks FM: Lipid-lowering therapy in acute coronary syndromes. JAMA. 2001, 285:1758–1760.

    Article  PubMed  CAS  Google Scholar 

  39. Heeschen C, Hamm CW, Laufs U, et al.: Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation. 2002, 105:1446–1452.

    Article  PubMed  CAS  Google Scholar 

  40. Blazing MA, De Lemos JA, Dyke CK, et al.: The A-to-Z trial: methods and rationale for a single trial investigating combined use of low-molecular weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. Am Heart J. 2001, 142:211–217.

    Article  PubMed  CAS  Google Scholar 

  41. National Cholesterol Education Program, Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (http://www.nhlbi.nih.gov/guidelines/cholesterol/index.htm). Latest lipid-lowering recommendations of the NCEP.

  42. Braunwald E, Antman EM, Beasley JW, et al.: ACC/AHA guidelines for the management of patients with unstable angina and non-ST segment elevation MI: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2000, 102:1193–1209. Latest recommendations of the ACC/AHA for management of patients with ACS.

    PubMed  CAS  Google Scholar 

  43. Smith SC, Blair SN, Bonow RO, et al.: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. J Am Coll Cardiol 2001, 38:1581–1583. Laest recommendations of the ACC/AHA for secondary prevention.

    Article  PubMed  Google Scholar 

  44. Bertrand ME, Simoons ML, Fox KAA, et al.: Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation; recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 2000, 21:1406–1432.

    Article  PubMed  CAS  Google Scholar 

  45. Fonarow GC, French WJ, Parsons LS, for the National Registry of MI 3: Use of lipid-lowering medications at discharge in patients with acute MI. Circulation. 2001, 103:38–44.

    PubMed  CAS  Google Scholar 

  46. Pearson TA, Peters TD, Feury D, for the ACCEPT Study: The American College of Cardiology Evaluation of Preventative Therapeutics (ACCEPT) study: attainment of goals for comprehensive risk reduction in patients with coronary disease in the US. J Am Coll Cardiol. 1998, 31:186A.

    Article  Google Scholar 

  47. Fonarow GC: Statin therapy after acute myocardial infarction: are we adequately treating high-risk patients? Current Atherosclerosis Reports. 2002, 4:99–106.

    PubMed  Google Scholar 

  48. EUROASPIRE II Study Group: Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J. 2001, 22:554–572.

    Article  Google Scholar 

  49. The GRACE Investigators: Rationale and design of the GRACE (global registry of acute coronary events) project: a multinational registry of patients hospitalized with acute coronary syndromes. Am Heart J. 2001, 141:190–199.

    Article  Google Scholar 

  50. Pearson TA, McBride PE, Miller NH, Smith SC: 27th Bethesda Conference: Task Force 8. Organization of preventive cardiology service. J Am Coll Cardiol. 1996, 27:1039–1047.

    Article  PubMed  CAS  Google Scholar 

  51. Fonarow GC, Gawlinski A, Moughrabi S, Tillsich JH: Improved treatment of coronary heart disease by implementation of a cardiac hospitalization atherosclerosis management program (CHAMP). Am J Cardiol. 2001, 87:819–822. CHAMP was one of the first programs to demonstrate the benefits of initiating lipid-lowering therapy (including statin therapy) before hospital discharge.

    Article  PubMed  CAS  Google Scholar 

  52. Mehta RH, Montoye CK, Gallogly M, et al.: Improving quality of care for acute myocardial infarction: the Guidelines Applied in Practice (GAP) initiative. JAMA. 2002, 287:1269–1276.

    Article  PubMed  Google Scholar 

  53. Henkin Y, Crystal E, Goldberg Y, et al.: Usefulness of lipoprotein changes during acute coronary syndromes for predicting postdischarge lipoprotein levels. Am J Cardiol. 2002, 89:7–11.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Preventive Cardiology Program, New York-Presbyterian Hospital, Columbia University College of Physicians and Surgeons, 622 West 168th Street, PH 10-203B, 10032, New York, NY, USA

    Lori Mosca MD, MPH, PhD & Angelo Biviano MD, MPH

Authors
  1. Lori Mosca MD, MPH, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Angelo Biviano MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mosca, L., Biviano, A. Lipid-lowering therapies in the management of acute coronary syndromes. Curr Cardiol Rep 4, 320–326 (2002). https://doi.org/10.1007/s11886-002-0068-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11886-002-0068-7

Keywords

Search

Navigation